ArticleJournal of microbiology and biotechnology2026
Bioactive Lipid Mediator Resolvin D5 Suppresses Melanogenesis in α-MSH-Stimulated B16F10 Cells via ROS-Associated p38/β-Catenin/MITF Regulation.
Article in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive melanin production contributes to hyperpigmentation disorders, highlighting the need for safer, mechanism-based depigmenting agents. This study investigated the anti-melanogenic effects of Resolvin D5 (RVD5) in α-MSH-stimulated B16F10 melanoma cells. RVD5 significantly reduced extracellular and intracellular melanin levels without compromising cell viability or cell number. Mechanistically, RVD5 suppressed tyrosinase expression and activity, accompanied by downregulation of MITF and β-catenin. RVD5 also dose-dependently inhibited α-MSH-induced phosphorylation of ERK1/2, p38, and JNK, while pharmacological inhibitor analysis suggested that p38 is a functionally dominant MAPK branch contributing to melanin output. In parallel, RVD5 reduced intracellular ROS levels, and the ROS scavenger NAC mimicked several effects of RVD5, supporting the involvement of ROS-associated signaling. Overall, RVD5 attenuates melanogenesis through antioxidant action, broad MAPK attenuation, and downregulation of the β-catenin/MITF/tyrosinase regulatory pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.